Hualan Biological EngineeringInc (002007) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hualan Biological EngineeringInc (002007) has a cash flow conversion efficiency ratio of 0.024x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥319.46 Million ≈ $46.75 Million USD) by net assets (CN¥13.25 Billion ≈ $1.94 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Hualan Biological EngineeringInc market cap and net worth for the company's overall valuation and market capitalisation.
Hualan Biological EngineeringInc - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Hualan Biological EngineeringInc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hualan Biological EngineeringInc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hualan Biological EngineeringInc ranked by their cash flow conversion efficiency. Explore Hualan Biological EngineeringInc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CMB.TECH NV
BR:CMBT
|
0.054x |
|
CSSC Offshore & Marine Engineering Group Co Ltd
SHG:600685
|
-0.073x |
|
First Capital Real Estate Investment Trust
TO:FCR-UN
|
0.008x |
|
Pacific Securities Co Ltd
SHG:601099
|
0.071x |
|
Mianyang Fulin Precision Machining Co Ltd
SHE:300432
|
0.033x |
|
Sinch AB
ST:SINCH
|
0.040x |
|
Daeduck Electronics Co Ltd
KO:353200
|
0.113x |
|
Bright Horizons Family Solutions Inc
NYSE:BFAM
|
0.101x |
Annual Cash Flow Conversion Efficiency for Hualan Biological EngineeringInc (2003–2024)
The table below shows the annual cash flow conversion efficiency of Hualan Biological EngineeringInc from 2003 to 2024. View Hualan Biological EngineeringInc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥13.85 Billion ≈ $2.03 Billion |
CN¥1.06 Billion ≈ $155.02 Million |
0.077x | -23.71% |
| 2023-12-31 | CN¥13.42 Billion ≈ $1.96 Billion |
CN¥1.35 Billion ≈ $196.94 Million |
0.100x | +27.90% |
| 2022-12-31 | CN¥12.21 Billion ≈ $1.79 Billion |
CN¥957.31 Million ≈ $140.08 Million |
0.078x | -50.39% |
| 2021-12-31 | CN¥9.06 Billion ≈ $1.33 Billion |
CN¥1.43 Billion ≈ $209.62 Million |
0.158x | -3.40% |
| 2020-12-31 | CN¥8.10 Billion ≈ $1.19 Billion |
CN¥1.33 Billion ≈ $193.93 Million |
0.164x | -17.35% |
| 2019-12-31 | CN¥6.88 Billion ≈ $1.01 Billion |
CN¥1.36 Billion ≈ $199.41 Million |
0.198x | -11.60% |
| 2018-12-31 | CN¥5.77 Billion ≈ $844.71 Million |
CN¥1.29 Billion ≈ $189.15 Million |
0.224x | +511.14% |
| 2017-12-31 | CN¥4.84 Billion ≈ $708.55 Million |
CN¥177.42 Million ≈ $25.96 Million |
0.037x | -50.74% |
| 2016-12-31 | CN¥4.44 Billion ≈ $649.04 Million |
CN¥329.94 Million ≈ $48.28 Million |
0.074x | -47.33% |
| 2015-12-31 | CN¥3.88 Billion ≈ $568.41 Million |
CN¥548.62 Million ≈ $80.28 Million |
0.141x | +3.30% |
| 2014-12-31 | CN¥3.64 Billion ≈ $532.05 Million |
CN¥497.15 Million ≈ $72.75 Million |
0.137x | -11.36% |
| 2013-12-31 | CN¥3.31 Billion ≈ $484.47 Million |
CN¥510.70 Million ≈ $74.73 Million |
0.154x | -11.73% |
| 2012-12-31 | CN¥2.83 Billion ≈ $414.24 Million |
CN¥494.69 Million ≈ $72.39 Million |
0.175x | +34.26% |
| 2011-12-31 | CN¥2.58 Billion ≈ $377.67 Million |
CN¥335.93 Million ≈ $49.16 Million |
0.130x | -48.63% |
| 2010-12-31 | CN¥2.41 Billion ≈ $352.04 Million |
CN¥609.53 Million ≈ $89.19 Million |
0.253x | -22.62% |
| 2009-12-31 | CN¥1.86 Billion ≈ $271.60 Million |
CN¥607.73 Million ≈ $88.93 Million |
0.327x | +132.43% |
| 2008-12-31 | CN¥1.14 Billion ≈ $167.42 Million |
CN¥161.18 Million ≈ $23.59 Million |
0.141x | -47.30% |
| 2007-12-31 | CN¥669.71 Million ≈ $98.00 Million |
CN¥179.02 Million ≈ $26.20 Million |
0.267x | +19.65% |
| 2006-12-31 | CN¥588.30 Million ≈ $86.09 Million |
CN¥131.43 Million ≈ $19.23 Million |
0.223x | +25.25% |
| 2005-12-31 | CN¥550.80 Million ≈ $80.60 Million |
CN¥98.24 Million ≈ $14.38 Million |
0.178x | +315.59% |
| 2004-12-31 | CN¥500.48 Million ≈ $73.24 Million |
CN¥21.48 Million ≈ $3.14 Million |
0.043x | +66.40% |
| 2003-12-31 | CN¥129.74 Million ≈ $18.98 Million |
CN¥3.35 Million ≈ $489.64K |
0.026x | -- |
About Hualan Biological EngineeringInc
Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, car… Read more